Skip to main content

Advertisement

Fig. 2 | Chinese Journal of Cancer

Fig. 2

From: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

Fig. 2

Kaplan–Meier estimates of the survival of standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI [luorouracil, leucovorin, oxaliplatin, and irinotecan] regimen) among mCRC patients with BRAF V600E mutation. mPFS median progression-free survival, mOS median overall survival

Back to article page